Acquisitions and License Agreements (Narrative) (Details) $ / shares in Units, $ in Millions							1 Months Ended	3 Months Ended								9 Months Ended	12 Months Ended			60 Months Ended
	Sep. 25, 2015 USD ($)	Apr. 16, 2015 USD ($)	Aug. 14, 2014 USD ($) $ / shares shares	Apr. 05, 2014 shares	Mar. 19, 2014 USD ($) $ / shares	Oct. 01, 2012 USD ($)	Jan. 31, 2014 USD ($)	Sep. 25, 2015 USD ($)	Jun. 26, 2015 USD ($)	Mar. 27, 2015 USD ($)	Dec. 26, 2014 USD ($)	Sep. 26, 2014 USD ($)	Jun. 27, 2014 USD ($)	Mar. 28, 2014 USD ($)	Dec. 27, 2013 USD ($)	Jun. 26, 2015 pharmacy_indications	Sep. 25, 2015 USD ($)	Sep. 26, 2014 USD ($)	Sep. 27, 2013 USD ($)	Sep. 27, 2013 USD ($)
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired																	$ 2,154.7	$ 2,793.8	$ 88.1
Net sales								$ 882.4	$ 877.3	$ 819.0	$ 768.2	$ 673.7	$ 530.1	$ 448.7	$ 429.5		3,346.9	2,082.0	1,712.3
Non-cash impairment charges																	0.0	381.2	0.0
Nuvo
Business Acquisition [Line Items]
Non-cash impairment charges																		11.1
Therakos
Business Acquisition [Line Items]
Contingent consideration	$ 0.0							0.0									0.0
Business Combination, Consideration Transferred, Other	1,300.0
Total consideration	1,019.7
Cash used to acquire business	1,000.0
Long Term Debt Assumed	300.0							300.0									300.0
Ikaria
Business Acquisition [Line Items]
Contingent consideration		$ 0.0
Business Combination, Consideration Transferred, Other		2,300.0
Total consideration		1,253.6
Cash used to acquire business		1,200.0
Long Term Debt Assumed		1,100.0
Net sales																	191.9	0.0
Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Contingent consideration			$ 0.0
Total consideration			$ 5,915.3
Amount of Cash Shareholders Receive, Per Share of Acquiree | $ / shares			$ 30.00
Amount of company shares shareholders will receive, per share | shares				0.897
Issuance of common stock to acquire business | shares			57,000,000
Issuance of senior unsecured notes to acquire business			$ 900.0
Issuance of senior secured term loan facility to acquire business			700.0
Cash used to acquire business			$ 150.0
Contingent consideration, potential maximum	190.0							190.0									190.0
Net sales																	1,125.9	129.2
Cadence Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Contingent consideration					$ 0.0
Total consideration					1,329.2
Net sales																	263.0	124.4
CNS Therapeutics, Inc.
Business Acquisition [Line Items]
Contingent consideration						$ 6.9
Payments to Acquire Businesses, Net of Cash Acquired						88.1
Total consideration						98.6
Contingent consideration, potential maximum						$ 9.0
Acthar | Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Number of indications that are approved for treatment | pharmacy_indications																19
Bristol-Myers Squibb | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																	25.0
Royalties paid																	43.9	13.2
Ofirmev | Cadence Pharmaceuticals, Inc. | Licensing Agreements
Business Acquisition [Line Items]
Milestone Payments																	10.0
Exalgo | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																	73.0
Royalties paid																	3.2	22.0	24.0
Milestone Payments																				$ 65.0
Depomed | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																	64.0
Milestone Payments																		10.0		22.0
Pennsaid | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																	120.0
Royalties paid																	1.8	$ 4.3	$ 3.9
Milestone Payments																				15.0
Finite-Lived Intangible Assets | Exalgo | Licensing Agreements
Business Acquisition [Line Items]
Milestone Payments																				$ 55.0
Royalty rights | Exalgo
Business Acquisition [Line Items]
Finite-lived intangible assets acquired							$ 7.2
Debentures | Therakos
Business Acquisition [Line Items]
Long term debt	750.0
Debentures | Ikaria
Business Acquisition [Line Items]
Long term debt		1,400.0
Revolving Credit Facility | Therakos
Business Acquisition [Line Items]
Borrowings, outstanding	$ 500.0							$ 500.0									$ 500.0
Revolving Credit Facility | Ikaria
Business Acquisition [Line Items]
Borrowings, outstanding		$ 240.0
Revolving Credit Facility | Revolving Credit Facility
Business Acquisition [Line Items]
Interest rate during period																	2.60%
Term loan due March 2021 | Revolving Credit Facility
Business Acquisition [Line Items]
Interest rate during period																	2.60%
Term loan due March 2021 | Secured Debt
Business Acquisition [Line Items]
Debt instrument, face amount					1,300.0
Interest rate during period																	3.25%
Term loan due March 2021 | Term Loan
Business Acquisition [Line Items]
Interest rate during period																	3.50%
Specialty Pharmaceuticals | Cadence Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Total consideration					$ 1,300.0
Amount of Cash Shareholders Receive, Per Share of Acquiree | $ / shares					$ 14.00